Shionogi has been granted a patent for compounds and methods that inhibit phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and diseases involving elevated levels of cytokines and proinflammatory mediators. The patent claims a method of treating or reducing symptoms of various PDE4-mediated diseases, including depression, anxiety, Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, by orally administering a specific oral pharmaceutical composition twice daily. The composition contains a compound with a specific structural formula in a dosage range of 10 mg to 200 mg. GlobalData’s report on Shionogi gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Shionogi, Cancer treatment biomarkers was a key innovation area identified from patents. Shionogi's grant share as of September 2023 was 54%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11767334B2) discloses a method for treating or reducing symptoms of various PDE4-mediated diseases. The method involves orally administering an oral pharmaceutical composition containing a compound with a specific structural formula. The composition is given twice daily and can contain between 10 mg to 200 mg of the compound.
The PDE4-mediated diseases that can be treated or have symptoms reduced by this method include depression, anxiety, degradation of learning and memory ability, Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease, late motor disorders, mild cognitive impairment, stroke, ischemia, depression secondary to illness, major depressive disorder, multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, transverse myelitis, amyotrophic lateral sclerosis, and arteriosclerotic dementia.
In particular, the method can be used for enhancing memory and cognition in patients with PDE4-mediated diseases. The same oral pharmaceutical composition is administered twice daily, containing between 10 mg to 200 mg of the compound. The enhancement of memory and cognition can be demonstrated through improvement in a scored behavior test.
The patent claims also specify different dosage options. In some cases, 10 mg of the compound is administered twice daily, while in other cases, 25 mg is administered twice daily. Importantly, the method claims that the compound can be administered without any adverse effects. However, if adverse effects do occur, they can include emesis (vomiting), central nervous system disturbances, or both.
This granted patent provides a method for treating or reducing symptoms of various PDE4-mediated diseases, including Alzheimer's disease, through the oral administration of a specific compound. The method also offers the potential for enhancing memory and cognition in patients with these diseases. The dosage options range from 10 mg to 200 mg, with specific options of 10 mg or 25 mg administered twice daily. The patent claims that the compound can be administered without adverse effects, but if any occur, they may include emesis or central nervous system disturbances. Further research and clinical trials may be necessary to validate the efficacy and safety of this method in treating PDE4-mediated diseases.
To know more about GlobalData’s detailed insights on Shionogi, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
